Copy to clipboard 
ORTHOWORLD estimates DePuy Synthes’ 2Q17 orthopaedic revenue at US $2,214.8MM, +0.4% vs. 2Q16. Segment sales and growth estimates on an as-reported basis are as follows for 2Q17 and 1H17.
| 2Q17 | 2Q16 | $ Change | % Change | |
| Joint Reconstruction | $847.8 | $844.9 | $2.8 | 0.3% |
| Knee | $391.4 | $390.8 | $0.6 | 0.2% |
| Hip | $356.4 | $354.8 | $1.6 | 0.5% |
| Extremities | $99.9 | $99.3 | $0.6 | 0.6% |
| Trauma | $611.0 | $603.2 | $7.8 | 1.3% |
| Arthroscopy/Soft Tissue | $179.3 | $174.8 | $4.5 | 2.6% |
| Spine | $380.7 | $391.6 | -$10.9 | -2.8% |
| Orthobiologics | $106.5 | $101.5 | $5.0 | 4.9% |
| Other (CMF) | $89.5 | $89.6 | -$0.1 | -0.1% |
| Total | $2,214.8 | $2,205.6 | $9.2 | 0.4% |
| 1H17 | 1H16 | $ Change | % Change | |
| Joint Reconstruction | $1,704.3 | $1,681.2 | $23.2 | 1.4% |
| Knee | $795.2 | $785.6 | $9.5 | 1.2% |
| Hip | $714.2 | $702.6 | $11.5 | 1.6% |
| Extremities | $195.0 | $192.9 | $2.1 | 1.1% |
| Trauma | $1,220.4 | $1,212.4 | $8.0 | 0.7% |
| Arthroscopy/Soft Tissue | $352.7 | $349.6 | $3.1 | 0.9% |
| Spine | $767.5 | $785.4 | -$17.9 | -2.3% |
| Orthobiologics | $206.7 | $202.4 | $4.3 | 2.1% |
| Other | $173.6 | $175.3 | -$1.7 | -1.0% |
| Total | $4,425.2 | $4,406.3 | $18.9 | 0.4% |
Estimated Codman neuro revenue, which was formerly reported by JNJ with its orthopaedic revenue,
has been removed from our figures for 2016 and 2017.
Performance highlights:
- Growth drivers: continued uptake of Corail primary stem and ATTUNE knee, offset by competition in Asia Pacific; TFNA nail; U.S. knee and trauma market growth
- Share loss in spine continues due to portfolio gaps, partially offset by arthroscopy/soft tissue repair, biologics (especially related to sports medicine), power tools
- Optimistic about 2H17 spine growth in light of Viper line extensions, launch of expandable cage acquired from Interventional Spine
- Additional 2H launches will include ATTUNE platform products
- Price pressure partially offset by favorable mix in knees, trauma, spine; net of mix, pricing update: Hips -2.6%, knees +0.3%, trauma +2%, spine -2.3%
- Completed acquisition of Tissue Regeneration Systems’ 3D printing technology to offer patient-specific, bioresorbable implants to treat orthopaedic and craniomaxillofacial deformities and injuries
- Announced acquisition of Sentio/nerve localization technology used in minimally invasive spine surgery; Sentio’s nerve mapping had been distributed worldwide in the past by companies such as Aurora Spine and LDR
- After the quarter’s close, introduced the single-use Distal Radius sterile instrument and implant kit; can reportedly address 80% of distal radius fracture cases currently treated with plates and screws
Sources: Johnson & Johnson; ORTHOWORLD Inc. estimates
ORTHOWORLD estimates DePuy Synthes’ 2Q17 orthopaedic revenue at US $2,214.8MM, +0.4% vs. 2Q16. Segment sales and growth estimates on an as-reported basis are as follows for 2Q17 and 1H17.
Q17
Q16
$ Change
% Change
Joint...
ORTHOWORLD estimates DePuy Synthes’ 2Q17 orthopaedic revenue at US $2,214.8MM, +0.4% vs. 2Q16. Segment sales and growth estimates on an as-reported basis are as follows for 2Q17 and 1H17.
| 2Q17 | 2Q16 | $ Change | % Change | |
| Joint Reconstruction | $847.8 | $844.9 | $2.8 | 0.3% |
| Knee | $391.4 | $390.8 | $0.6 | 0.2% |
| Hip | $356.4 | $354.8 | $1.6 | 0.5% |
| Extremities | $99.9 | $99.3 | $0.6 | 0.6% |
| Trauma | $611.0 | $603.2 | $7.8 | 1.3% |
| Arthroscopy/Soft Tissue | $179.3 | $174.8 | $4.5 | 2.6% |
| Spine | $380.7 | $391.6 | -$10.9 | -2.8% |
| Orthobiologics | $106.5 | $101.5 | $5.0 | 4.9% |
| Other (CMF) | $89.5 | $89.6 | -$0.1 | -0.1% |
| Total | $2,214.8 | $2,205.6 | $9.2 | 0.4% |
| 1H17 | 1H16 | $ Change | % Change | |
| Joint Reconstruction | $1,704.3 | $1,681.2 | $23.2 | 1.4% |
| Knee | $795.2 | $785.6 | $9.5 | 1.2% |
| Hip | $714.2 | $702.6 | $11.5 | 1.6% |
| Extremities | $195.0 | $192.9 | $2.1 | 1.1% |
| Trauma | $1,220.4 | $1,212.4 | $8.0 | 0.7% |
| Arthroscopy/Soft Tissue | $352.7 | $349.6 | $3.1 | 0.9% |
| Spine | $767.5 | $785.4 | -$17.9 | -2.3% |
| Orthobiologics | $206.7 | $202.4 | $4.3 | 2.1% |
| Other | $173.6 | $175.3 | -$1.7 | -1.0% |
| Total | $4,425.2 | $4,406.3 | $18.9 | 0.4% |
Estimated Codman neuro revenue, which was formerly reported by JNJ with its orthopaedic revenue,
has been removed from our figures for 2016 and 2017.
Performance highlights:
- Growth drivers: continued uptake of Corail primary stem and ATTUNE knee, offset by competition in Asia Pacific; TFNA nail; U.S. knee and trauma market growth
- Share loss in spine continues due to portfolio gaps, partially offset by arthroscopy/soft tissue repair, biologics (especially related to sports medicine), power tools
- Optimistic about 2H17 spine growth in light of Viper line extensions, launch of expandable cage acquired from Interventional Spine
- Additional 2H launches will include ATTUNE platform products
- Price pressure partially offset by favorable mix in knees, trauma, spine; net of mix, pricing update: Hips -2.6%, knees +0.3%, trauma +2%, spine -2.3%
- Completed acquisition of Tissue Regeneration Systems’ 3D printing technology to offer patient-specific, bioresorbable implants to treat orthopaedic and craniomaxillofacial deformities and injuries
- Announced acquisition of Sentio/nerve localization technology used in minimally invasive spine surgery; Sentio’s nerve mapping had been distributed worldwide in the past by companies such as Aurora Spine and LDR
- After the quarter’s close, introduced the single-use Distal Radius sterile instrument and implant kit; can reportedly address 80% of distal radius fracture cases currently treated with plates and screws
Sources: Johnson & Johnson; ORTHOWORLD Inc. estimates
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
